전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,132 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleFollicular Lymphoma FoundationPhase 1

huCART19-IL18-eDHFR cells (huCART19-IL18-eDHFR cells)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMinerva Biotechnologies Corpora…Phase 1

huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells (huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleMinerva Biotechnologies Corpora…Phase 1

huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D (huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleZhujiang HospitalPhase 1

humanized CD19 CAR-T Cells with TLR2 (humanized CD19 CAR-T Cells with TLR2)

B Lymphoblastic Leukemia/Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells (i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells)

Relapsed Neuroblastoma; Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T Cell Therapy (iC9-CAR.B7-H3 T Cell Therapy)

Breast Cancer; Relapse · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T cell infusion (iC9-CAR.B7-H3 T cell infusion)

Pancreas Cancer; Relapse · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T cells (iC9-CAR.B7-H3 T cells)

Ovary Neoplasm; Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe V FoundationPhase 1

iC9-CAR19 T cells (iC9-CAR19 T cells)

Lymphoma; Lymphoma, B-Cell · Lymphoma

#Lymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBellicum PharmaceuticalsPhase 1

iC9.GD2.CAR.IL-15 T Infusion (iC9.GD2.CAR.IL-15 T Infusion)

Lung Cancer; Small Cell Lung Carcinoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9.GD2.CAR.IL-15 T-cells (iC9.GD2.CAR.IL-15 T-cells)

Neuroblastoma; Osteosarcoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMarino Biotechnology Co., Ltd.Phase 1

iPD1 CD19 eCAR T cells (iPD1 CD19 eCAR T cells)

Relapsed or Refractory B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastalePeking Union Medical CollegePhase 2

iparomlimab + tuvonralimab (iparomlimab + tuvonralimab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#monoclonal-antibody#PrecisionTherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversitätsklinikum Hamburg-Ep…Phase 3

Isa-KD (isatuximab/carfilzomib/dexamethasone, isatuximab/carfilzomib/dexamethasone (Isa-KD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Universittsklinikum
Trials 1Status Discontinued
AntibodyLimited DatastalePeking Union Medical CollegePhase 2

ivonescimab + investigator-choice platinum doublet+ (ivonescimab + investigator-choice platinum doublet+)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#monoclonal-antibody#PrecisionTherapy+1
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPreclinical

lentiviral-based CART meso therapy (lentiviral-based CART meso therapy)

Subjects Who Have Received Lentiviral-based CART-meso Therapy · Multi-target

#Multi-target#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

mCD19-CAR-CD28-CD3-zeta. (anti-CD19 CAR, mCD19-CAR-CD28-CD3-zeta., mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL))

Hematologic Malignancies; Hematologic Neoplasms · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

pCAR-19B cells (pCAR-19B cells)

Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleVaccinex Inc.Phase 2

pembrolizumab (Keytruda, pepinemab + pembrolizumab)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) · Recurrent/Metastatic Squamous Cell Carci

#RecurrentMetastaticSquamousCellC#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

peripheral blood progenitor cells carrying MDR1 (peripheral blood progenitor cells carrying MDR1)

Breast Neoplasms; Neoplasm Metastasis · Breast Neoplasms

#BreastNeoplasms#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active

56 / 57 pages

← PreviousNext →